NCT05872685 is a Phase 2 clinical trial of S1 in Adenocarcinoma of the Stomach, sponsored by Yu jiren.

Who is sponsoring NCT05872685?

NCT05872685 is sponsored by Yu jiren.

What drugs are being tested in NCT05872685?

Interventions in NCT05872685: S1, Oxaliplatin, Serplulimab, Placebo.

What condition does NCT05872685 study?

NCT05872685 studies Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair.

Is NCT05872685 still recruiting?

NCT05872685 is currently recruiting now. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT05872685

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Recruiting now Phase 2 Last updated 17 January 2024

What this trial tests

Phase 2 trial testing S1 in Adenocarcinoma of the Stomach in 314 participants. Currently enrolling.

Timeline

24 December 2023

Primary endpoint
30 April 2026

30 April 2029

Quick facts

Lead sponsor	Yu jiren
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	314
Start date	24 December 2023
Primary completion	30 April 2026
Estimated completion	30 April 2029
Sites	5 locations across China

Drugs / interventions tested

S1 — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Serplulimab — full drug profile →
Placebo

Conditions studied

Adenocarcinoma of the Stomach — all drugs for Adenocarcinoma of the Stomach →
Adenocarcinoma of Esophagogastric Junction — all drugs for Adenocarcinoma of Esophagogastric Junction →
Proficient Mismatch Repair — all drugs for Proficient Mismatch Repair →

Sponsor

Yu jiren — full company profile →

Who can join

Adults 18 to 80, any sex, with Adenocarcinoma of the Stomach or Adenocarcinoma of Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma with proficient mismatch repair

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of S1

Trials testing the same drug.

NCT07038629 — Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC · Phase 2 · recruiting
NCT05970627 — Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastri · Phase 2 · not yet recruiting
NCT05729646 — Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · Phase 2 · recruiting
NCT05822453 — Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma · Phase 2 · not yet recruiting
NCT05774964 — Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases · Phase 2 · unknown

Other recruiting trials for Adenocarcinoma of the Stomach

Currently open trials in the same condition.

NCT05729646 — Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · Phase 2 · recruiting
NCT05715931 — Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri · Phase 2 · recruiting
NCT06121700 — Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer · Phase 2 · recruiting
NCT04878783 — Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG · active not recruiting

Other Yu jiren trials

Trials by the same sponsor.

NCT05970627 — Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastri · Phase 2 · not yet recruiting
NCT05729646 — Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · Phase 2 · recruiting
NCT05715931 — Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri · Phase 2 · recruiting
NCT04515615 — Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05872685 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yu jiren
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05872685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing